The goal of this research project proposal is to develop a physiologic model of ex vivo tumor culture to study responsiveness to immune checkpoint blockade. Although inhibitors of the PD-1/PD-L1 and CTLA4 immune checkpoints have led to remarkable and durable responses in cancers such as malignant melanoma, the ability to predict the activity for individual patients remains limited, and have relied on measurements from fixed tumor tissue. While the ability to grow patient derived tumors in organoid models, for example, has been rigorously demonstrated over the past several years, these systems lack key features of the tumor microenvironment, including a vascular network and immune cells. Thus, an ex vivo system that supports tumor and immune cell culture by recapitulating a physiologic microenvironment will almost certainly be essential to the development of functional assays that can predict patient response to immunotherapy. Recently, we demonstrated that our three-dimensional microfluidic culture system can support growth of primary human tumor spheroids derived from multiple different cancer types, including melanoma. Importantly, immune profiling of the cells within the spheroids reveals that they also contain a significant proportion of tumor associated immune cells, including macrophages, dendritic cells, and antigen experienced T lymphocytes. Exposure of these short term spheroid cultures to immune checkpoint inhibitors such as anti- PD1 antibodies results in evidence of immunologic response and robust cytokine secretion into conditioned medium, as well as evidence of cell killing in some cases. The broad, long term objective of this proposal is to extend this preliminary model to leverage the capabilities developed in our labs to incorporate a microcirculatory network in the 3D matrix surrounding the tumor and use this as a means of subsequently introducing selected myeloid cells. Both the initial model and these extensions to it will be subject to detailed validation in order to develop a realistic physiologic culture system that enables prediction of immunotherapy response. A unique aspect of this work is that it spans basic and translational research, including the use of animal models to help engineer vascularized networks, and patient-derived samples and clinical response to immune checkpoint blockade to validate the system.
Specific aims are to: 1) Refine and validate an existing microfluidic tumor culture model to assess response to immune checkpoint inhibitor therapies 2) Incorporate vascular flow of immune cells to monitor extravasation and expansion of immune effector cells in tumor culture, and 3) Directly compare ex vivo experiments with patient specific response to immune checkpoint blockade. Through these complementary studies, the ultimate goal is to develop a robust model that can eventually be adapted to clinical use to help target immune checkpoint inhibitor therapies to the appropriate subgroup of patients. This basic platform will also be useful in other settings, once it has been fully evaluations
The goal of the proposed research is to extend the capabilities and extensively evaluate a novel in vitro tumor model assay to study tumor immune responses directly in patient samples. Although the development immune checkpoint blockade (anti-PD-1/PD-L1 and anti-CTLA4 inhibitors) has represented a major advance and is effective across multiple cancer types, response rates remain low overall, and predictive markers of efficacy are lacking. By constructing a physiologic culture system in which to examine tumor responsiveness to these agents prior to treating a patient, these studies have the potential to have a direct and significant impact on public health.
